Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
ACADIA PharmaceuticalsACAD +1.20%78 Net Cash per Share is $3.02 as of Jun. 2026, which is 72% below its 10-year median of 10.60. GuruFocus rates ACAD with a GF Score™ of 78/100 and a GF Value™ of $25.05 (Modestly Overvalued). The stock has 10 warning signs investors should review. Among 757 Biotechnology companies, ACADIA Pharmaceuticals ranks worse than 69.88% on this metric.
ACADIA Pharmaceuticals (NAS:ACAD) Net Cash per Share Explanation
Ben Graham invested in situations where the company's stock price was lower than its net-cash. He assigned some value to the company's other current asset. The value is called Net Current Asset Value (NCAV). One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Graham's strategy produced similar results.
You can find companies that are traded below their Net Current Asset Value (NCAV) with our Net-Net screener.
ACADIA Pharmaceuticals Net Cash per Share Related Terms
ACADIA Pharmaceuticals Net Cash per Share Historical Data
* Premium members only.
The historical data trend for ACADIA Pharmaceuticals's Net Cash per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ACAD vs LEGN, TNGX, CAI: Net Cash per Share Comparison
For the Biotechnology subindustry, ACADIA Pharmaceuticals's Price-to-Net-Cash, along with its competitors' market caps and Price-to-Net-Cash data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
ACADIA Pharmaceuticals Price-to-Net-Cash vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, ACADIA Pharmaceuticals's Price-to-Net-Cash distribution charts can be found below:
* The bar in red indicates where ACADIA Pharmaceuticals's Price-to-Net-Cash falls into.
ACADIA Pharmaceuticals Net Cash per Share Calculation
In the calculation of a company's Net Cash per Share, assets other than cash and short term investments are considered to be worth nothing. But the company has to pay its debt and other liabilities in full. This is an extremely conservative way of valuation. Most companies have negative Net Cash per Share. But sometimes a company's price may be lower than its net-cash.
ACADIA Pharmaceuticals's Net Cash per Share for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ACADIA Pharmaceuticals (ACAD) has a Net Cash per Share of $3.02 as of Jun. 2026. Net cash per share equals the per-share value of cash and equivalents less total liabilities and minority interest. View historical data on ACADIA Pharmaceuticals and its competitors. This is 72% below median its historical median of 10.60. Over the past decade, ACADIA Pharmaceuticals' Net Cash per Share has ranged from 5.63 to 45.30. According to the industry distribution chart, ACADIA Pharmaceuticals ranks #529 out of 757 companies in the Biotechnology industry, placing it in the top 69.9%.
Is ACADIA Pharmaceuticals' Net Cash per Share too high?
ACADIA Pharmaceuticals' current Net Cash per Share of $3.02 is 72% below median its 10-year median of 10.60. Over the past 10 years, this metric has ranged from a low of 5.63 to a high of 45.30. The Biotechnology industry median Net Cash per Share is 5.17. ACADIA Pharmaceuticals' value of $3.02 is 41.6% below this industry median. Based on the distribution chart, ACADIA Pharmaceuticals ranks #529 out of 757 companies in the Biotechnology industry, which is below the industry midpoint. Overall, ACADIA Pharmaceuticals has a GF Score™ of 78/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does ACADIA Pharmaceuticals' Net Cash per Share compare to LEGN and TNGX?
According to the Biotechnology industry distribution chart, ACADIA Pharmaceuticals ranks #529 out of 757 companies for Net Cash per Share. This places ACADIA Pharmaceuticals in the lower half of its industry. The industry median Net Cash per Share is 5.17. ACADIA Pharmaceuticals' value of $3.02 is 41.6% below this benchmark. Historically, ACADIA Pharmaceuticals' own Net Cash per Share has ranged from 5.63 to 45.30 over the past decade. While the company's 10-year median is 10.60 vs. the industry median of 5.17, ACADIA Pharmaceuticals has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Cash per Share for a Biotechnology company?
The median Net Cash per Share among Biotechnology companies is 5.17, based on 757 companies in the industry. Companies in the top quartile (top 25%) have a Net Cash per Share significantly above this median, while those in the bottom quartile fall well below. However, Net Cash per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. ACADIA Pharmaceuticals's current Net Cash per Share of $3.02 is 41.6% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Cash per Share mean?
A high Net Cash per Share can signal that a stock is expensive relative to its fundamentals. Net cash per share equals the per-share value of cash and equivalents less total liabilities and minority interest. View historical data on ACADIA Pharmaceuticals and its competitors. For the Biotechnology industry, the median Net Cash per Share is 5.17 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. ACADIA Pharmaceuticals's current Net Cash per Share is $3.02, which is 72% below median its own 10-year median of 10.60. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ACADIA Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, ACADIA Pharmaceuticals (ACAD) is currently considered Modestly Overvalued. The stock's GF Value™ is $25.05, compared to a current price of $29.40 — trading 17.4% above its estimated fair value. The current Net Cash per Share is $3.02, which is 72% below median its 10-year median of 10.60 and 41.6% below the Biotechnology industry median of 5.17. ACADIA Pharmaceuticals' overall GF Score™ is 78/100 with 10 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Cash per Share calculated?
Net Cash per Share is calculated from a company's financial statements. For ACADIA Pharmaceuticals (ACAD), the current Net Cash per Share is $3.02 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is ACADIA Pharmaceuticals (ACAD) Overvalued in 2026?
Based on GuruFocus' analysis, ACADIA Pharmaceuticals stock appears to be overvalued.
The current stock price of $29.40 is trading 17.4% above its estimated GF Value™ of $25.05.
GuruFocus considers ACADIA Pharmaceuticals to be Modestly Overvalued.
Key valuation signals for ACAD:
Net Cash per Share: $3.02 (72% below median its 10-year median of 10.60)
GF Value™: $25.05 vs. price of $29.40 (17.4% above fair value)
Industry Position: 41.6% below the Biotechnology median (#529 of 757)
No single metric tells the full story. See the ACAD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases. It has two core franchises in neuroscience and neuro-rare diseases. The neuroscience franchise is anchored by its commercial product NUPLAZID (pimavanserin), which is used for the treatment of hallucinations and delusions associated with Parkinson's Disease Psychosis (PDP). The neuro-rare disease franchise is anchored by the commercial product DAYBUE, which is used for the treatment of Rett syndrome. In addition, the company has various product candidates under development in different stages, including ACP-204, ACP-211, ACP-711, ACP-2591, etc.
78GF Score
Get the complete analysis for ACAD
Net Cash per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ACAD has been successfully added to your 
